Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

georgecantstansya 31 posts  |  Last Activity: Jul 24, 2015 5:45 PM Member since: Sep 12, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • georgecantstansya by georgecantstansya Jul 24, 2015 5:45 PM Flag

    I forgot to send straws w/ Jett for day w/friends/bros on boat, can not only open his own beer now, drinks w/out straw.

    I like his style!!

    Sentiment: Strong Buy

  • Reply to

    FDA will accept the NDA on....

    by beaverfan12345678 Jul 21, 2015 6:01 AM
    georgecantstansya georgecantstansya Jul 21, 2015 7:52 AM Flag

    Thursday

  • georgecantstansya georgecantstansya Jul 20, 2015 8:39 AM Flag

    Calendar

    Sentiment: Strong Buy

  • Reply to

    Nice 273,000 Block Went Out......

    by georgecantstansya Jun 30, 2015 4:02 PM
    georgecantstansya georgecantstansya Jun 30, 2015 4:36 PM Flag

    With that being the case blank, 273k is a large block for SRPT at the close. Is there anything that can read into this? How about that it was at the ask?

  • Reply to

    Nice 273,000 Block Went Out......

    by georgecantstansya Jun 30, 2015 4:02 PM
    georgecantstansya georgecantstansya Jun 30, 2015 4:21 PM Flag

    Showed up as 1 trade on my E*trade time and sales. What are you using?

  • georgecantstansya by georgecantstansya Jun 30, 2015 4:02 PM Flag

    at the ask right as the market closed.

    Sentiment: Strong Buy

  • georgecantstansya by georgecantstansya Jun 29, 2015 9:23 PM Flag

    Robert W. Baird notes, "This morning's news that Sarepta has submitted its NDA to the FDA for eteplirsen and that Biomarin's NDA for drisapersen has been accepted incrementally increases our confidence that the FDA is showing an inordinate amount of flexibility when it comes to DMD. We continue to believe SRPT shares could see triple digits if eteplirsen is approved, which we would expect to hear on or before Leap Day 2016, and like the risk/reward at these levels."

    Sentiment: Strong Buy

  • yawn.

    No problem jrrt1.

  • georgecantstansya by georgecantstansya Jun 29, 2015 8:29 AM Flag

    Roth Capital analyst Debjit Chattopadhyay said news that Sarepta Therapeutic (NASDAQ: SRPT) completed the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen is a "significant de-risking event.' The firm maintained its Buy rating and price target of $45.00.

    Chattopadhyay commented, "Sarepta announced the completion of its NDA submission ahead of our mid-July expectation, setting itself up for a late fall panel meeting, and 1Q16, conditional approval. Recall that Sarepta is seeking accelerated and not full approval, which would be contingent upon the ongoing studies. Importantly, despite its poor data and lack of mechanistic rationale (dystrophin), BioMarin is not conducting additional studies, indirectly ceding competitive advantage to Sarepta, in our view."

    Sentiment: Strong Buy

  • georgecantstansya by georgecantstansya Jun 29, 2015 7:06 AM Flag

    it's official/

    Sentiment: Strong Buy

  • georgecantstansya by georgecantstansya Jun 24, 2015 7:50 AM Flag

    looks like another up day for us longs.

    Sentiment: Strong Buy

  • Reply to

    Canaccord Upgrade

    by georgecantstansya Jun 15, 2015 7:19 AM
    georgecantstansya georgecantstansya Jun 15, 2015 9:59 AM Flag

    You are correct bigcn1145, I now see what I posted was a 3rd party commenting on that earlier upgrade. The date of the article was today however.

    Sentiment: Strong Buy

  • georgecantstansya by georgecantstansya Jun 15, 2015 7:19 AM Flag

    Canaccord Genuity upgrades its view on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the counter had a rating of Hold. Canaccord Genuity raises the price target from $16 per share to $30 per share on Sarepta Therapeutics, Inc.. For the current week, the company shares have a recommendation consensus of Buy.

    The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares has been rated as hold from 11 Wall Street Analysts. 3 analysts have suggested buy for the company.

    Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose by 3.67% in the past week and 82.05% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 3.61% and the outperformance increases to 84.54% for the last 4 weeks.

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT) witnessed a decline in the market cap on Friday as its shares dropped 2.16% or 0.61 points. After the session commenced at $28.11, the stock reached the higher end at $28.19 while it hit a low of $27.15. With the volume soaring to 732,622 shares, the last trade was called at $27.69. The company has a 52-week high of $33.41. The company has a market cap of $1,148 million and there are 41,466,000 shares in outstanding. The 52-week low of the share price is $11.33.

    The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Officer (SVP & Chief Medical Officer) of Sarepta Therapeutics, Inc., Kaye Edward M. Md, had purchased 800 shares in a transaction dated on February 27, 2015. The transaction was executed at $11.81 per share with total amount equaling $9,448. The company shares have dropped 15.45% in the past 52 Weeks. On June 17, 2014 The shares registered one year high of

    Sentiment: Strong Buy

  • Reply to

    that 4/30 short interest is most interestng

    by simp08801 Jun 9, 2015 4:27 PM
    georgecantstansya georgecantstansya Jun 9, 2015 5:25 PM Flag

    I hope the shorts decide to cover and go long. Can you imagine what double the buying would do!! Whoever blinks first could start quite the tsunami. This could make the ICPT move look like child's play.

    Sentiment: Strong Buy

  • georgecantstansya by georgecantstansya Jun 9, 2015 9:58 AM Flag

    It's interesting with the new draft guidance, SRPT up, and BMRN and PTCT down. I think this portends the future.

    Sentiment: Strong Buy

  • For what it's worth.

  • Reply to

    Biomarin and PTC, are you serious?

    by benwarren638 Jun 5, 2015 8:36 AM
    georgecantstansya georgecantstansya Jun 5, 2015 9:00 AM Flag

    Good catch bf109gee.

  • Reply to

    UCLA Letter...

    by bionerd51 Jun 3, 2015 1:12 PM
    georgecantstansya georgecantstansya Jun 3, 2015 10:19 PM Flag

    A tad more of the letter:

    For our son Dylan, access to a skipping drug that induces some dystrophin expression is reasonably

    likely to extend the length of time he is able to feed himself and hug his parents. He and the many other

    boys with DMD cannot long endure delays in the approval of these agents, which should move forward

    irrespective of potential improvements in dystrophin quantification.

    The opportunity to do what is best for patients and to perform rigorous scientific testing that drives

    confirmation of efficacy do not always go hand in hand. As highlighted in the workshop, in the case of

    exon skipping drugs, patient advocacy and scientific rigor both benefit from FDASIA guidance. In this

    instance, allowing approval of initial exon skipping drugs based on evidence of dystrophin restoration in

    muscle biopsies allows access to drugs that are reasonably likely to predict clinical benefit and

    simultaneously enables a path for exploring the limits and benefits of more precise dystrophin

    quantitation as dosing, additional exons, and modifications are inevitably explored in clinical trials. We

    strongly favor a route of approval that allows companies working in the space to develop better

    quantification, while not holding the drug approval process hostage to the desire for an improved

    biomarker.

    We note that improvements and reliance on dystrophin quantification as a surrogate biomarker will

    necessitate continued and perhaps repeated patient muscle biopsy, which we, as parents and scientists,

    wholeheartedly support in order to facilitate a more rapid path to approval. These additional data will be

    key to the field for multiple different new and potentially highly effective therapies. Acceptance of

    existing dystrophin measurements as reasonably likely to predict clinical benefit will encourage continued

    biopsy and drive the development of more even robust assays, while premature rejection of this already

    informative measure will discourage biops

    Sentiment: Strong Buy

  • Reply to

    Need your HELP

    by christine.mcsherry Jun 2, 2015 2:01 PM
    georgecantstansya georgecantstansya Jun 2, 2015 2:33 PM Flag

    Just voted too, back in the lead but can't get comfortable.

    Sentiment: Strong Buy

  • Reply to

    Monday is June 1

    by simp08801 May 29, 2015 5:25 PM
    georgecantstansya georgecantstansya May 30, 2015 7:18 AM Flag

    Be careful betthenews, if hero sees that post he's going to get very angry.

    Sentiment: Strong Buy